Using IL-10NanoCap® to treat Familial Adenomatous Polyposis

Who could benefit from this research

What this research studies

This research focuses on developing an oral treatment called FAPXIL, which is a sustained-release formulation of Interleukin-10 aimed at managing Familial Adenomatous Polyposis (FAP). The project builds on previous successful pre-clinical work and aims to optimize treatment protocols while ensuring safety and effectiveness. It involves extensive testing in animal models and plans to meet with the FDA to discuss the next steps towards human clinical trials. Patients may benefit from a new therapeutic option that could reduce the progression of polyps and associated colon cancer.

Why it matters

Where this research is happening

• Therapyx, INC.
  Buffalo, United States Active

Researchers

• Principal investigator: Auci, Dominick — Therapyx, INC.
• Study coordinator: Auci, Dominick

Related research

Other NIH-funded projects on the same topics.

• Classifying duodenal polyps in familial adenomatous polyposis

  This project will test two risk models to see if they better predict dangerous duodenal polyps and cancer risk in people with genetically confirmed FAP.

  Recruiting at 2 sites Fondazione IRCCS Istituto Nazionale dei Tumori, Milano · Milan, MI and 1 other locations · NCT07199127

• Personalized home treadmill exercise for people with Familial Adenomatous Polyposis (FAP)

  This trial will try different amounts of home treadmill exercise in people with FAP who have at least five rectal polyps to see if exercise can help prevent polyps from coming back.

  Recruiting University of Michigan Rogel Cancer Center · Ann Arbor, Michigan and 1 other locations · NCT06641310

• Investigating factors that influence polyp development in patients with Familial Adenomatous Polyposis

  This study looks at how gut bacteria and environmental factors might affect polyp growth in people with Familial Adenomatous Polyposis who have had preventive surgery and regular check-ups.

  Recruiting at 2 sites Hospices Civils de Lyon · Lyon, France and 1 other locations · NCT06614738

• TPST-1495 treatment for people with familial adenomatous polyposis

  This trial will try an oral drug called TPST-1495 to see if it reduces the number of polyps in the small bowel and colon in people with familial adenomatous polyposis.

  Recruiting at 2 sites Phase 2 National Cancer Institute (NCI) · Phoenix, Arizona and 3 other locations · NCT06557733

• 10 cm versus 15 cm J-shaped ileal pouch after IPAA surgery

  This trial will see if a 10 cm or a 15 cm J-pouch gives better bowel function and quality of life for people having IPAA for ulcerative colitis or familial adenomatous polyposis.

  Recruiting at 2 sites Odense University Hospital · Aarhus and 1 other locations · NCT06538402

• ONC201 (dordaviprone) for safety and prevention of colorectal polyps in high-risk adults.

  This trial tests whether different doses of ONC201 (dordaviprone) are safe and can help prevent new colorectal polyps in adults with familial adenomatous polyposis or a history of multiple adenomas.

  Recruiting at 3 sites Phase 1 National Cancer Institute (NCI) · Ann Arbor, Michigan and 4 other locations · NCT05630794

About this research

1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.